This profile was last updated on .
Is this you? Claim your profile.
+ Get 10 Free Contacts a Month
68 T.W. Alexander Drive
Research Triangle Park, North Carolina 27709
T3D Therapeutics, Inc. is a privately-held, Research Triangle Park, NC-based company incorporated in 2013. The Company has an exclusive license to T3D-959, its lead product candidate, and a platform of structurally-related molecules. T3D Therapeutics' mis ... more
President and Chief Executive Officer
Chief Executive Officer
Associate Director Biology
The University of Connecticut
Bachelor of Arts
University of Connecticut
University of Vermont Medical College
The University of Vermont College of Medicine
T3D Therapeutics Announces Presentation of Phase 2a Preliminary Results of T3D-959 in Alzheimer's Subjects at the 2016 Alzheimer's Association International Conference
T3D received approval from the Food and Drug Administration's Division of Neurology Products.
In March, T3D received a $1.8 million federal grant to support the Phase 2 trial, which is expected to involve 36 patients.
T3D-959 has demonstrated encouraging results in experiments with lab rats that hold out the promise that it could slow or even halt the progress of Alzheimer's, Didsbury said in March.
Founded in 2013, T3D is a virtual company that relies on outsourcing.
It currently has two full-time and one-part time employee.
A Research Triangle Park drug development startup company is looking to raise money to further studies of a drug candidate that was originally targeted as a treatment for diabetes as a treatment for Alzheimer's disease.
Irwin Allen News Network
The Hartford Financial Services Group , Inc.
Iveco Trucks New Zealand Ltd.
The Patron Spirits Company